Michael Mazowiecki, MD
Neurology · Greensburg, PANPI 1841304581
Payments from drug & device makers
Across 923 payments — averaging $580.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$88K
- Biogen$78K
- EMD Serono, Inc.$70K
- Acorda Therapeutics, Inc$55K
- Biohaven Pharmaceuticals, Inc.$45K
- Biohaven Pharmaceutical Holding Company Ltd.$38K
- plus $161K from 22 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 219 | $88,415 |
| Biogen | 72 | $77,763 |
| EMD Serono, Inc. | 129 | $69,521 |
| Acorda Therapeutics, Inc | 58 | $55,190 |
| Biohaven Pharmaceuticals, Inc. | 45 | $44,713 |
| Biohaven Pharmaceutical Holding Company Ltd. | 39 | $38,481 |
| Genentech USA, Inc. | 44 | $38,404 |
| Sanofi | 54 | $38,168 |
| E.r. Squibb & Sons, L.L.C. | 45 | $37,505 |
| Pfizer | 32 | $14,945 |
| Lilly USA, LLC | 19 | $8,216 |
| Bristol Myers Squibb | 70 | $7,083 |
| Harmony Biosciences LLC | 14 | $5,787 |
| Johnson & Johnson | 15 | $5,309 |
| UCB, Inc. | 7 | $1,681 |
| TG Therapeutics, Inc. | 11 | $1,438 |
| AstraZeneca | 10 | $567 |
| Novartis | 11 | $531 |
| Neurocrine Biosciences, Inc. | 4 | $379 |
| Livanova USA, Inc. | 5 | $340 |
| Amgen | 4 | $260 |
| Mallinckrodt Hospital Products Inc. | 9 | $167 |
| Greenwich Biosciences, Inc. | 1 | $128 |
| Lundbeck LLC | 2 | $125 |
| Mallinckrodt Enterprises LLC | 1 | $122 |
| MDD US Operations, LLC | 1 | $122 |
| SK Life Science, Inc. | 1 | $120 |
| Bausch Health US, LLC | 1 | $25 |
How this compares
$535,508 in reported general payments places this provider in the 95th percentile of 941 neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Greensburg
- David WeismanAbington$9.3M
- Amit Bar-OrPhiladelphia$7.7M
- Thomas LeistPhiladelphia$5.8M
- Jan DrappatzPittsburgh$4M
- Lauren ElmanPhiladelphia$3.3M
- David IrwinPhiladelphia$2.5M
- Paula ClemensPittsburgh$2.1M
- Anoopum GuptaPittsburgh$2M
- Daniel KremensPhiladelphia$1.9M
- Frances JensenPhiladelphia$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.